vs
Side-by-side financial comparison of Astria Therapeutics, Inc. (ATXS) and GAXOS.AI INC. (GXAI). Click either name above to swap in a different company.
GAXOS.AI INC. is the larger business by last-quarter revenue ($1.2M vs $706.0K, roughly 1.8× Astria Therapeutics, Inc.). GAXOS.AI INC. runs the higher net margin — -77.2% vs -4482.0%, a 4404.8% gap on every dollar of revenue.
Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for rare hematological and allergic diseases with high unmet medical needs. Its core pipeline includes drug candidates designed to address life-threatening immune-mediated conditions, serving patient populations across North America and other global markets with limited existing treatment options.
ATXS vs GXAI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $706.0K | $1.2M |
| Net Profit | $-31.6M | $-957.9K |
| Gross Margin | — | — |
| Operating Margin | -4830.6% | -99.0% |
| Net Margin | -4482.0% | -77.2% |
| Revenue YoY | — | 94996.3% |
| Net Profit YoY | -29.0% | -15.1% |
| EPS (diluted) | $-0.55 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.2M | ||
| Q3 25 | $706.0K | $498.3K | ||
| Q2 25 | — | $171.0K | ||
| Q3 24 | $0 | — | ||
| Q2 24 | — | $0 |
| Q4 25 | — | $-957.9K | ||
| Q3 25 | $-31.6M | $-1.0M | ||
| Q2 25 | — | $-749.4K | ||
| Q3 24 | $-24.5M | — | ||
| Q2 24 | — | $-809.2K |
| Q4 25 | — | -99.0% | ||
| Q3 25 | -4830.6% | -263.9% | ||
| Q2 25 | — | -574.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | -77.2% | ||
| Q3 25 | -4482.0% | -201.0% | ||
| Q2 25 | — | -438.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | $-0.13 | ||
| Q3 25 | $-0.55 | $-0.14 | ||
| Q2 25 | — | $-0.11 | ||
| Q3 24 | $-0.42 | — | ||
| Q2 24 | — | $-0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $227.7M | $840.5K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $233.3M | $13.1M |
| Total Assets | $271.9M | $13.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $840.5K | ||
| Q3 25 | $227.7M | — | ||
| Q2 25 | — | — | ||
| Q3 24 | $344.3M | — | ||
| Q2 24 | — | $4.5M |
| Q4 25 | — | $13.1M | ||
| Q3 25 | $233.3M | $14.1M | ||
| Q2 25 | — | $15.0M | ||
| Q3 24 | $341.7M | — | ||
| Q2 24 | — | $4.7M |
| Q4 25 | — | $13.4M | ||
| Q3 25 | $271.9M | $14.3M | ||
| Q2 25 | — | $15.4M | ||
| Q3 24 | $361.6M | — | ||
| Q2 24 | — | $5.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-32.3M | $-733.1K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-733.1K | ||
| Q3 25 | $-32.3M | $-1.1M | ||
| Q2 25 | — | $-716.9K | ||
| Q3 24 | $-28.0M | — | ||
| Q2 24 | — | $-738.5K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | $-28.0M | — | ||
| Q2 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
